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OBJECTIVES This study sought to compare the safety, efficacy and clinical utility of the Amplatzer septal
occluder (ASO) for closure of secundum atrial septal defect (ASD) with surgical closure.
BACKGROUND The clinical utility of a device such as the ASO can only be judged against the results of
contemporaneous surgery.
METHODS A multicenter, nonrandomized concurrent study was performed in 29 pediatric cardiology
centers from March 1998 to March 2000. The patients were assigned to either the device or
surgical closure group according to the patients’ option. Baseline physical exams and
echocardiography were performed preprocedure and at follow-up (6 and 12 months for device
group, 12 months for surgical group).
RESULTS A total of 442 patients were in the group undergoing device closure, whereas 154 patients
were in the surgical group. The median age was 9.8 years for the device group and 4.1 years
for the surgical group (p  0.001). In the device group, 395 (89.4%) patients had a single
ASD; in the surgical group, 124 (80.5%) (p  0.008) had a single ASD. The size of the
primary ASD was 13.3  5.4 mm for the device group and 14.2  6.3 mm for the surgery
group (p  0.099). The procedural attempt success rate was 95.7% for the device group and
100% for the surgical group (p  0.006). The early, primary and secondary efficacy success
rates were 94.8%, 98.5% and 91.6%, respectively, for the device group, and 96.1%, 100% and
89.0% for the surgical group (all p  0.05). The complication rate was 7.2% for the device
group and 24.0% for the surgical group (p  0.001). The mean length of hospital stay was
1.0  0.3 day for the device group and 3.4  1.2 days for the surgical group (p  0.001).
Mortality was 0% for both groups.
CONCLUSIONS The early, primary and secondary efficacy success rates for surgical versus. device closure of
ASD were not statistically different; however, the complication rate was lower and the length
of hospital stay was shorter for device closure than for surgical repair. Appropriate patient
selection is an important factor for successful device closure. Transcatheter closure of
secundum ASD using the ASO is a safe and effective alternative to surgical repair. (J Am
Coll Cardiol 2002;39:1836–44) © 2002 by the American College of Cardiology Foundation
Atrial septal defect (ASD) is a common form of congenital
heart disease accounting for approximately 10% of all
congenital cardiac defects (1). Surgical closure of ASD has
been practiced for more than 45 years, and has been
considered the standard treatment for patients with secun-
dum ASD (2). Since the first attempt in 1976 by King and
Mills (3), transcatheter closure of secundum ASD has
evolved over the past three decades, and is being increas-
ingly used in recent years (4–14). The Amplatzer septal
occluder (ASO) is one of the commonly used devices.
Previous reports have demonstrated that this device is safe
and easy to use with a high success rate (12–15). This study
was designed to directly compare the safety, efficacy and
clinical utility of ASO for closure of secundum ASD with
concurrent surgical repair results in a multicenter nonran-
domized trial.
METHODS
Organization and eligibility criteria. Between March
1998 and March 2000, 29 pediatric cardiology centers with
experience in transcatheter and surgical treatment of con-
genital heart disease participated in this trial. The study was
approved by the institutional review board of each center
and by the U.S. Food and Drug Administration (FDA)
under an investigator-initiated Investigational Device Ex-
emption. After the investigators have been selected, quali-
fied and trained, patients with secundum ASD who were
eligible for closure were enrolled. A monitor was designated
to oversee the compliance with the study protocol.
Patients were enrolled into device or surgical closure
group. The inclusion criteria for both groups included:
1) the presence of a secundum ASD (diameter of 38 mm
by echocardiography for the device group; no limit for the
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surgical group); 2) a left-to-right shunt with a Qp/Qs ratio
of 1.5:1 or the presence of right ventricular volume
overload: and 3) patients with minimal shunt in the pres-
ence of symptoms (arrhythmias, transient ischemic attacks).
Additional inclusion criteria for the device group required
the presence of a distance of 5 mm from the margins of
the ASD to the coronary sinus, atrioventricular valves and
right upper pulmonary vein as measured by echocardiogra-
phy. Exclusion criteria for both groups included: 1) the
presence of associated congenital cardiac anomalies requir-
ing surgical repair; 2) primum ASD; 3) sinus venosus ASD
(including partial anomalous pulmonary venous drainage);
4) pulmonary vascular resistance 7 Woods units; 5) a
right-to-left shunt at the atrial level with a peripheral
arterial saturation94%; 6) patients with recent myocardial
infarction; and 7) unstable angina and decompensated
congestive heart failure and patients with right and/or left
ventricular decompensation with ejection fraction of 30%.
An additional exclusion criterion for the device group was
patients with multiple defects that could not be adequately
covered by device(s). Also excluded from the study were
patients with: 1) sepsis; 2) history of repeated pulmonary
infection; 3) any type of serious infection 1 month before
the procedure; 4) malignancy where life expectancy was 2
years; 5) intracardiac thrombi; 6) weight 8 kg; 7) inability
to obtain informed consent; and 8) other contraindications
to aspirin or other antiplatelet agents.
Once a patient met the enrollment criteria, the patient or
the guardian was fully informed of the treatment options,
then decided which option they would choose with their
cardiologists. Nine participating institutions did not offer
device closure during the study period. The collection of
data was largely prospective; however, in 21 centers offering
device closure, surgical patients were permitted to be en-
rolled retrospectively as well as prospectively if the surgery
was performed after the date the IRB in that institution had
approved the device closure protocol. This was done in an
effort to expedite enrollment in the surgical arm and to
ensure that the surgical data were contemporaneous. In-
formed consent was obtained from all patients or their
guardians.
Device and delivery system. The ASO (AGA Medical
Corp., Golden Valley, Minnesota) is a self-centering device
made of 0.004 to 0.0075 in Nitinol wire. A full description
of the device has been reported previously (12, 13). In brief,
the device consists of two expandable round discs with a
4-mm long connecting waist. Polyester mesh was added to
the left and right atrial discs and the connecting waist to
enhance thrombogenicity. The device size is dictated by the
diameter of its waist. The device was available in various
sizes ranging from 4 to 38 mm. The two flat discs extend
radially beyond the central waist to provide secure anchor-
age. Both discs are angled slightly towards each other to
ensure firm contact with the atrial septum. The delivery
system consists of a cable, loader, delivery sheath and dilator
and a pin vise. The delivery sheath initially had a platinum
marker band at its tip. However, because of embolization of
this band in three patients, this marker band has been
removed.
Device implantation or surgical procedure. The protocol
of device closure has been reported previously in detail
(12,13). Briefly, all procedures were performed under gen-
eral anesthesia with endotracheal intubation and with con-
tinuous transesophageal echocardiographic (TEE) monitor-
ing. After percutaneous entry of the femoral vein, a
complete hemodynamic evaluation was performed. This was
followed by an angiogram in the right upper pulmonary vein
in the hepatoclavicular projection to further delineate the
atrial septum. A sizing balloon catheter was introduced over
an extra-stiff guide wire positioned in the left upper pulmo-
nary vein to measure the balloon stretched diameter. Two
methods of sizing (pulling technique and the stationary
balloon dilation technique) were followed. The device
chosen for closure was within 2 mm of the balloon-stretched
diameter. The appropriate size device equivalent to the
stretched diameter was then screwed on the cable and
advanced inside the proper size sheath (6–14F). The sheath
was usually positioned over the guide wire inside the left
upper pulmonary vein or in the middle of the left atrium.
Under fluoroscopic and TEE guidance, both discs of the
device were deployed across the defect. Once the device has
been deployed and released, repeat TEE and angiogram
were performed to assess the result of closure. A dose of an
appropriate antibiotic was given during the procedure and
two doses at 8 h interval were given after. Patients were
usually observed overnight and discharged home the follow-
ing day. All patients were instructed about infective endo-
carditis prophylaxis for a total of six months after device
placement. Aspirin 3–5 mg/kg was initiated 48 h before
closure and continued for six months after.
For patients who underwent surgical closure, standard
ASD repair under general endotracheal anesthesia was
performed (2). The right atrium was opened after a ster-
notomy. The ASD was closed either by direct suture or
using a pericardial or Goretex patch (W.L. Gore Associates,
Flagstaff, Arizona). Patients were discharged home after
three to five days in the hospital, depending on their clinical
condition.
Echocardiographic interpretations. Experienced echocar-
diographers from the participating institutions interpreted
all echocardiograms (procedural and follow-up points). A
study was classified to have complete closure, trivial residual
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shunt, small residual shunt, moderate residual shunt or large
residual shunt according to a protocol reported by Boutin et
al. (9). All of these echocardiograms were sent on SVHS
tapes to the data management center at the manufacturing
company’s headquarters. Echocardiograms of 108 patients
in the device group and 87 patients in the surgical group
were reviewed and interpreted by two independent expe-
rienced echocardiographers from institutions not partic-
ipating in the trial. There were no discrepancies between
the original interpretation and those of the independent
reviewers.
Follow-up and end point measurements. Patients who
had device closure underwent a physical examination, an
electrocardiogram, a chest radiograph and a transthoracic
echocardiogram (TTE) with color Doppler at 24 h, six
months and one year after the procedure. Patients who had
surgical closure underwent the same tests at discharge from
the hospital and at one-year follow-up.
Patients were considered to have successful ASD closure
if they had no, trivial (1-mm color jet width) or small
(color jet width 1 to 2 mm) residual shunt as assessed by
color Doppler echocardiography. Patients with moderate
(color jet width 2–4 mm) or large (color jet width 4 mm)
residual shunts were considered to have a failed procedure.
End point measures for clinical utility were: 1) early efficacy
success: successful closure of the defects by a device or
operation without major complication, surgical reinterven-
tion, embolization or moderate or large residual shunt at
discharge from hospital; 2) primary efficacy success (12-
month success): successful closure of the ASD within 12
months postprocedure without the need for surgical repair;
and 3) secondary efficacy success: successful device or
surgical attempt in the absence of a major complication, or
a surgical reintervention within the study period (March
1998 to March 2000).
Safety was defined as the absence of death or major
complications, by a monitoring board at the manufacturer’s
headquarters that was organized to classify the events as
major and minor complications. Major complications in-
cluded cerebral embolism, cardiac perforation with tampon-
ade, endocarditis, repeat operation, death due to the proce-
dure, cardiac arrhythmias requiring permanent pacemaker
placement or long-term antiarrhythmic medication, or de-
vice embolization requiring immediate surgical removal.
Minor complications included device embolization with
percutaneous retrieval, cardiac arrhythmia with treatment,
phrenic nerve injury, access site hematoma, other vascular
access site complications, retroperitoneal hematoma, surgi-
cal wound complications and other procedural complica-
tions, as listed in the protocol. Pericardial effusion requiring
medical management, evidence of device-associated throm-
bus formation without embolization (with or without treat-
ment) and marker band embolization without known se-
quelae are also considered as minor complications.
Sample size and data analysis. Sample size estimates were
based on published statistics formulae (16). Previous studies
have demonstrated rates of device and surgical closure to be
between 90% and 98% (2,12,13). Therefore, 106 patients
per study arm would be needed to provide an 80% proba-
bility of finding a significant difference using a one-tailed
test at the 0.05 level. With an increase of 15% to allow for
possible attrition, 125 patients in each study arm were
required to yield a power over 80%.
Comparability of the retrospective and prospective surgi-
cal patients was performed before pooling the data for
comparisons to the device group (in order to ascertain that
there were no systematic differences between these two
groups). Binary data were analyzed using Fisher’s exact test.
Comparisons of continuous data measured at baseline for
the study groups were analyzed using Welch’s modified t
test, assuming the possibility of unequal variances. Mann-
Whitney U test was used to compare the age between two
groups because it was not normally distributed. Cox pro-
portional hazards regression models were computed for the
device and surgical group. Covariate analysis was used to
find potential risks for complication. Confidence intervals
(CI) were calculated as appropriate. SPSS 10.0 for Win-
dows (SPSS Inc., Chicago, Illinois) was used for the
analysis. Data are expressed as mean  SD or median and
range as appropriate. A value of 0.05 was considered
statistically significant.
RESULTS
Study subjects. A total of 614 patients were enrolled in the
study. Figure 1 demonstrates the patient flow diagram. Four
hundred forty-two patients with device closure and 154
patients with surgical closure satisfied the inclusion criteria
and were included as subjects in each arm of the study.
Comparability of treatment groups. Thirty-seven patients
in the surgical arm were collected retrospectively and 117
patients were collected prospectively. Justification analysis
between the two groups of patients (retrospective vs. pro-
spective) in the surgical arm demonstrated no differences in
age, right ventricular enlargement, incidence of multiple
ASDs, ASD size, length of hospital stay, and success and
complication rate. Therefore, the data from both groups
were pooled for analysis and comparison with the device
group. Furthermore, there was no difference in gender
distribution in either device group or surgical group, or
among various trial centers (All p  0.05). Table 1
demonstrates the demographic and baseline clinical data in
each group. Patients in the device group were older and had
a higher incidence of hypertension and stroke, whereas
patients in the surgical group had a higher incidence of
failure to thrive, respiratory infections, right axis deviation
on electrocardiogram and multiple ASDs. The two groups
had similar primary ASD size and right atrial and ventric-
ular dilation.
Comparison of closure results. Of 442 patients in the
device group, 423 patients had 433 devices successfully
deployed (95.7%) across the atrial septum. Four hundred
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thirteen patients received one device and 10 patients re-
ceived two devices for multiple ASDs. In the other 19
(4.3%) patients, the attempt at securing a device across the
atrial septum failed because of various reasons: 1) ASD was
too large for the available device (n  5); 2) insufficient
atrial septal rim (n 6); 3) anomalous right pulmonary vein
connection (n  6); and 4) marker band embolization (n 
1). One patient had immediate device embolization neces-
sitating surgical removal.
The mean balloon stretched diameter of the primary
ASD was 17.8  6.2 mm (range 6 to 40 mm) and of the
secondary ASD was 8.7 1.4 mm (range 5 to 23 mm). The
Figure 1. Flow diagram of all patients enrolled in the study. *Intent to treat was defined as patients that were screened for participation in the clinical trial
and signed the informed consent. However, there was no attempt to place a device at that procedure due to various reasons (too large atrial septal defect
for the available device, insufficient rim, or did not meet inclusion criteria). IRB  Institutional Review Board.
Table 1. Comparison of Demographic and Baseline Clinical Data Between Device and Surgical
Closure Group
Device Patients
(n  442)
Surgical Patients
(n  154) p Values
Age (yrs) 18.1  19.3 5.9  6.2  0.001*
(range) (0.6–82.0) (0.6–38.2)
Gender (female/male) 299/143 94/60 0.140
Height (cm) 134.6  32.0 105.5  26.9  0.001
Weight (kg) 42.3  27.3 20.6  15.2  0.001
Medical history
Congestive heart failure 11 (2.5%) 7 (4.5%) 0.271
Failure to thrive 14 (3.2%) 13 (8.4%) 0.012
Coronary heart disease 9 (2.0%) 0 0.121
Respiratory infections 7 (1.6%) 13 (8.4%)  0.001
COPD 1 (0.2%) 0 1.000
TIA 6 (1.4%) 1 (0.6%) 0.684
Hypertension 16 (3.6%) 0 0.016
Stroke 13 (2.9%) 0 0.026
Recurrent stroke/TIA 5 (1.1%) 1 (0.6%) 1.000
Diabetes 4 (0.9%) 0 0.577
Pulmonary ejection murmur 281 (63.6%) 94 (61.0%) 0.628
Cardiomegaly by X-ray 293/424 (69.1%) 118 (76.6%) 0.096
Right axis deviation in ECG 126/439 (28.7%) 72/153 (47.1%)  0.001
Number of multiple ASDs 47 (10.6%) 30 (19.4%) 0.008
Primary ASD size (mm) 13.3  5.4 14.2  6.3 0.099
Right atrium enlargement 379/434 (85.7%) 134/151 (89.3%) 0.774
Right ventricle enlargement 413/439 (94.1%) 146/152 (96.1%) 0.412
*Mann-Whitney U test.
ASD  atrial septal defect; COPD  chronic obstructive pulmonary disease; ECG  electrocardiogram; TIA  transient
ischemic attack.
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mean Qp/Qs ratio was 2.1  0.8 (range 0.7 to 7.7). Of the
441 patients in whom data described the direction of atrial
shunting, 404 (91.6%) had a left-to-right shunt, 34 (7.7%)
had a bidirectional shunt and 3 (0.7%) had a right-to-left
shunt. The mean device size for the primary ASD was
18.1  6.1 mm (range 6 to 38 mm) and 10.4  4.2 mm
(range 6 to 20 mm) for the secondary ASD. The mean
fluoroscopy time was 20.7  12.8 min (range 3.3 to
75.5 min). A total of 413 patients (97.6%) (95% CI 95.7%
to 98.9%) had immediate successful closure, including 130
(30.7%) with complete closure, 227 (53.7%) with trivial
residual shunt and 56 (13.2%) with small residual shunt.
Ten patients (2.4%) had moderate (n  7) or large (n  3)
residual shunt.
In the surgical closure group, all patients had a successful
operation. The comparison of immediate closure results,
procedure time and length of hospital stay are demonstrated
in Table 2.
At 24-h follow-up, 409 patients (96.7%) (95% CI 94.5%
to 98.2%) in the device group had successful closure,
including 307 (72.6%) with complete closure, 40 (9.5%)
with trivial residual shunt and 62 (14.7%) with small
residual shunt. Fourteen (3.3%) patients had moderate (n
11) or large (n  3) residual shunt. Twenty-four patients
from the surgical group had echocardiographic data avail-
able at 24 h. All had complete closure.
A total of 387 (91.5%) patients in the device group had
complete six-month follow-up. Of those, 376 patients had
successful closure. Therefore, the success rate at the six-
month follow-up was 97.2% (95% CI 95.0% to 98.6%).
Eleven patients (2.8%) had moderate (n  9) or large (n 
2) residual shunt. Because the six-month follow-up was not
part of the surgical follow-up protocol, only 19 surgical
patients had six-month follow-up data. All had successful
closure (one patient had trivial residual shunt) as docu-
mented by color Doppler TTE.
At 12-month follow-up, 331 patients from the device
group had their evaluation completed. Of those, 326 pa-
tients had successful closure. Therefore, the success rate was
98.5% (95% CI 96.5% to 99.5%). Five (1.5%) patients had
moderate (n  4) or large (n  1) residual shunt. One
hundred nine patients from the surgical group completed
the 12-month follow-up. Ninety-four had color Doppler
TTE examination, and all had a successful closure (four
patients had trivial residual and three patients had small
residual shunt). Of the remaining 60 patients in the surgical
group, five were excluded because of IRB lapse, 14 were
confirmed closed at six months by TTE and 41 were assumed
closed at the 12-month follow-up. Comparison of clinical
outcomes between the two groups is demonstrated in Table 2.
Although closure results at 24-month follow-up was not
the end point measure of this study, 52 patients from the
device group had their 24-month evaluation. Forty-nine
had complete closure, two had small residual shunt and one
Table 2. Comparison of Outcomes Between Device and Surgical Closure Groups
Device Patients Surgical Patients p Values
Procedure attempt success 423/442 (95.7%) 154/154 (100%) 0.006
Procedure attempt failure* 19/442 (4.3%) 0
Immediate procedure success 413/423 (97.6%) 154/154 (100%) 0.070
Moderate residual shunt 7/423 (1.7%) 0
Large residual shunt 3/423 (0.7%) 0
Early efficacy success† 401/423 (94.8%) 148/154 (96.1%) 0.663
Moderate residual shunt 13/442 (2.9%) 0
Large residual shunt 3/442 (0.6%) 0
Device embolization 5/442 (1.1%) N/A
Major complication 1/442 (0.2%) 6/154 (3.9%) 0.002
Procedure success at six months 376/387 (97.2%) 154/154 (100%) 0.039
Moderate residual shunt 9/387 (2.3%) 0
Large residual shunt 2/387 (0.5%) 0
Primary efficacy success‡ 326/331 (98.5%) 149/149 (100%) 0.331
Moderate residual shunt 4/331 (1.2%) 0
Large residual shunt 1/331 (0.3%) 0
Secondary efficacy success¶ 405/442 (91.6%) 137/154 (89.0%) 0.330
Major complication 1/442 (0.2%) 8/154 (5.2%)  0.001
Cardiac arrhythmias treated 12/442 (2.7%) 9/154 (5.8%) 0.078
Surgical reintervention 5/442 (1.1%) 0 0.335
Procedure time (min) 105.7  43.2 159.7  54.1  0.001
Length of hospital stay (day) 1.0  0.3 3.4  1.2  0.001
*Procedure failure: patients who were screened for participation in the device group. However, device was not deployed because
of atrial septal defect (ASD) too large for the device available at the time (n  5), insufficient rim (n  6), other anatomical
conditions including anomalous right pulmonary vein connection or atrial septal aneurysm (n  6) or delivery system failure
(marker band embolization) (n  1). One patient (0.2%) had acute embolization of the device to the right ventricle. †Success
of device or surgical closure without major complication, surgical reintervention, embolization and moderate or large residual
shunt at discharge from hospital. ‡Successful closure of the ASD within 12 months postprocedure without the need for surgical
repair. ¶Success of a device or surgical attempt if there had been no major complication, cardiac arrhythmias requiring treatment,
or a surgical reintervention.
N/A  not available.
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had moderate residual shunt. Thus the successful closure
rate was 98.1%. The five patients with residual shunt (four
moderate, one large) at the 12-month follow-up were
evaluated at the two-year follow-up. Three of these patients
had spontaneous closure of their shunt; one had a second
procedure with implantation of a second device had com-
plete closure and one patient still had large residual shunt
being followed medically. No data on 24-month follow-up
were available for the surgical group.
Comparison of complications. There was no device-or
surgical-related death in either group. Table 3 summarizes
the complications encountered during the study period.
Seven major complications occurred in the device group.
Device or marker band embolization requiring surgical
removal was the most common complication, which oc-
curred in four patients in three different hospitals. Cardiac
arrhythmias requiring major treatment occurred in two
patients. Complete atrioventricular block was found at
six-month follow-up in a 6-year old girl with an 11-mm
ASD and aneurysm of the atrial septum. The patient had
sinus rhythm alternating with slow junctional rhythm doc-
umented by 24-h ambulatory electrocardiogram before the
procedure (17). A DVD Thera DR pacemaker (Medtronic
Inc., Minneapolis, Minnesota) was implanted. Atrial fibril-
lation occurred in an 81-year-old patient requiring antiar-
rhythmic medication. Cerebral embolism occurred in a
14-year-old girl with a 17-mm ASD. This patient had an
episode of numbness and weakness in her right leg, right
arm and the right side of her mouth seven days after the
procedure. These symptoms resolved completely within
20 min. The patient had a normal neurological evaluation at
the six-month follow-up.
Eight major complications were encountered in the
surgical group. These included pulmonary edema and large
pericardial effusion requiring two pericardiocentesis and
prolonged intensive care unit stay in one patient; large
pericardial effusion with tamponade requiring pericardio-
centesis or catheter drainage in three patients; repeat surgery
because of a large amount of drainage from the chest tube in
two patients and surgical wound complications requiring
sternal wire removal and other treatments in two patients.
The incidence of major complications was higher in the
surgical group by Fisher’s exact test (p  0.030). Cox
proportional hazards regression models also indicated that
the device group had lower rates of major complications
(p  0.013). Because of the small number of major
complications, covariate analysis was not done.
Minor complications occurred in 27 patients in the device
group and 29 in the surgical group (p  0.001) (Table 3).
Two embolized devices were successfully retrieved percuta-
neously in the catheterization laboratory in two patients.
The most common minor complication was cardiac arrhyth-
mias in both groups. The incidence of any complications
was significantly greater in the surgical group (p  0.001).
Table 3. Comparison of Complications Between Device and Surgical Closure Groups
Device Group
(n  442)
Surgical Group
(n  154) p Values
Major complications (total) 7 (1.6%) 8 (5.4%) 0.030
Cardiac arrhythmias requiring major treatment* 2 (0.5%) 0 1.000
Device embolism with surgical removal 3 (0.2%) 0 0.572
Marker band embolism with surgical removal 1 (0.2%) 0 1.000
Cerebral embolism with extremity numbness 1 (0.2%) 0 1.000
Pericardial effusion with tamponade 0 3 (1.9%) 0.017
Pulmonary edema 0 1 (0.6%) 0.258
Repeat surgery 0 2 (1.3%) 0.066
Surgical wound complications 0 2 (1.3%) 0.066
Minor complications (total) 27 (6.1%) 29 (18.8%)  0.001
Anemia 0 1 (0.6%) 0.258
Allergic reaction (drug) 2 (0.5%) 0 1.000
Cardiac arrhythmias requiring minor treatment† 15 (3.4%) 9 (5.2%) 0.232
Device embolism with percutaneous removal 2 (0.5%) 0 1.000
Headaches/possible TIA 2 (0.5%) 0 1.000
Marker band embolism 2 (0.5%) 0 1.000
Post pericardiotomy syndrome 0 2 (1.3%) 0.066
Pericardial effusion 0 6 (3.9%)  0.001
Pleural effusion 0 1 (0.6%) 0.258
Staph infection 0 1 (0.6%) 0.258
Surgical wound complications 0 1 (2.6%) 0.258
Thrombus formation 3 (0.2%) 0 0.572
Transfusions 0 2 (1.3%) 0.066
Upper respiratory infection/fever 0 2 (1.3%) 0.066
Urinary tract disturbance 1 (0.2%) 0 1.000
Total complications (patient basis) 32 (7.2%) 37 (24.0%)  0.001
*One patient in the device group had two major cardiac arrhythmia complications. †One patient in device group had two minor
cardiac arrhythmia complications.
TIA  transient ischemic attack.
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Cox proportional hazards regression models also demon-
strated that the device group had significantly lower rates of
complications (p 0.001). Adding covariates of age, history
of congestive heart failure, failure to thrive and respiratory
infection did not change this conclusion. None of the
covariates contributed significantly to the Cox regression
model. Figure 2 demonstrates the curves of probability of
freedom from any complications in the device and surgical
groups. All but one patient with complications (major or
minor) returned for the one-year follow-up; all were well
with no sequelae.
DISCUSSION
The ASO is a relatively new device for transcather closure of
secundum ASD (12–14,18) Its main advantages include:
the self-centering mechanism, leading to better complete
closure rates; delivery through relatively small introducing
sheaths; and simple placement technique and retrievability
before release. Previous clinical studies have compared the
closure results of this device with historical surgical series
(12–15). This is the first multicenter controlled study for the
efficacy, clinical utility and safety of the ASO for closure of
secundum ASD by comparison with concurrent surgical
closure results.
Comparisons of efficacy and utility. Surgical closure of
ASD has been considered the standard treatment for ASD
for more than 45 years (2). Although the perioperative
mortality in most cardiac surgical centers approaches zero,
residual shunting after surgical closure is not rare, and its
incidence varies from 2% to 7.9% in the long-term
follow-up data (19,20).
In this study, the 12-month follow-up of our 94 surgical
patients with color Doppler TTE data indicated no residual
shunt in 87 patients. Seven patients had trivial (n  4) and
small (n  3) residual shunts. Even assuming that all
surgical patients had successful closure, the early, primary
and secondary efficacy success rates were not significantly
higher than in the patients who underwent device closure of
their ASDs. This is in accordance with a previous report
from a single institution with a large experience in surgical
and device closure of ASD (21). Their 61 patients with
ASD who underwent closure using the ASO had the same
immediate successful closure rate (98%) achieved by open
surgical repair. Therefore, our multicenter study confirms
that the efficacy and utility of ASO for closing secundum
ASD is the same as those of surgical closure.
In our study, 4.3% of patients in the device group had a
failed procedural attempt for various reasons. Most of these
failures were due to the large size of ASD and the
unavailability of larger devices at the time. With the
availability of larger devices (34 mm in diameter), some of
those patients could have undergone successful closure of
their ASD. The ASO manufacturer has also modified the
delivery sheath by removing the marker band positioned at
the tip of the sheath to prevent further embolization of the
marker band. Anatomical conditions such as insufficient
Figure 2. Comparison of curves of freedom from complication probability between device group and surgical group. Lighter lines beside each curve are
the 95% confidence interval levels.
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rims or the presence of anomalous pulmonary drainage are
limitations for device closure of ASD. Therefore, although
transcatheter closure of ASD by an ASO has similar efficacy
to surgical closure, surgical intervention will still be required
for patients with defects unsuitable for device closure.
Comparison of safety. The mortality in both groups of
patients was zero. This is in accordance with the previous
reports in the current era (2,10–13,22–24). However, there
were complications in both surgical patients and device
closure patients. Most of the major complications in the
surgical patients were due to large pericardial effusion with
tamponade or other severe symptoms. Pericardiocentesis or
catheter drainage was required to treat the effusion. Thus,
these patients required prolonged intensive care unit or
hospital stay and other treatments. Minor morbidity oc-
curred in 17.8% of the surgical patients. Those complica-
tions were mainly cardiac arrhythmias and pericardial effu-
sion. The overall morbidity in this surgical cohort was lower
than previously reported in other series (24). Galal et al.
reported a major complication rate of 8.8%, a moderate
complication rate of 6.1% and a mild complication rate of
67% in their 232 adult patients who underwent surgical
repair of isolated secundum ASD. This difference might
have been due to the younger age of our surgical patients.
Other complications of surgical ASD repair reported by
others such as sepsis, renal failure (24), duodenal ulcer (21)
and atrial flutter/fibrillation identified at long-term follow-up
(25,26) were not encountered in our patients.
One patient who underwent device closure had a rare
major complication of a cerebral embolism. This patient had
complete recovery.
Cardiac arrhythmias and conduction abnormalities were
the most common complications encountered. Although
most of these were transient, one patient required pace-
maker implantation. Another problem of device closure is
the chance of device embolization, which occurred in 1.1%
of the patients in this study. But this still compares favorably
with previous studies using either the ASO or other devices
(4,21). For patients with embolization occurring during or
immediately after the procedure, the device could be easily
retrieved percutaneously in the catheterization laboratory or
by operation. One patient who came for follow-up inadver-
tently after one week from implantation was found to have
a 24-mm device embolized to the pulmonary artery. This
patient was playing American football within 72 h from
closure. The device was successfully retrieved in the cathe-
terization laboratory. The manufacturer has recommended
no contact sports for a month and has also recommended a
chest radiograph after one week in all patients after that
case. We believe that device embolization can be prevented
or minimized. Most of the cases of embolization occurred
during the early learning curve of the operators. Increased
operator experience and the use of TEE during implanta-
tion should minimize this complication.
Nevertheless, our study indicates that the overall compli-
cation rate was much lower in the device closure patients
than the current surgical patients. Furthermore, there are
other potential advantages favoring device closure of ASD.
These include avoidance of thoracotomy and cardiopulmo-
nary bypass and shortened hospital stay, with less use of
hospital resources with potential money saving. Addition-
ally, there are other advantages that could not be objectively
measured. These include the psychological advantages for
patients and their families and the economic use of time for
family and patients due to the shorter recuperation period
(27). The use of fluoroscopy to guide device placement is a
disadvantage; however, the fluoroscopy time needed to
implant the ASO is short and compares favorably with other
devices (7,9,10,11). Radiation time can be reduced further
with increased operator experience and with the aggressive
use of TEE or intracardic echocardiographic monitoring of
the procedure (28). Some investigators even have performed
catheter closure of ASD using the ASO under TEE
guidance alone without fluoroscopy (29). We believe that
the use of TEE with judicious use of fluoroscopy should
result in improved success and minimize device emboliza-
tion. Finally, the U.S. FDA has approved the ASO for
routine clinical use in children and adults with secundum
ASD. Furthermore, the FDA required formal supervised
training of physicians planning to use the ASO for closure
of ASD. The manufacturer requires physicians planning to
use the device to be proctored by a physician experienced in
the use of ASO.
Study limitations. The first limitation of this study is that
the design was not a randomized trial. It would have been
difficult if not impossible to perform a randomized study for
ASD closure for many logistic and ethical reasons. The
second limitation is that the two groups of patients were not
comparable in age and in number of patients with multiple
ASDs. The disparity in age was due to a high number of
adult patients in the device group that were referred by
cardiologists in centers not involved with transcatheter
device closure. The age disparity explains the differences in
body weight and height. Nevertheless, although the device
group included a large number of adult patients with age up
to 82 years, which might have increased the chance of
complications, the efficacy was similar to and the complica-
tion rate was lower than surgical patients. Furthermore, the
incidence of complications in the surgical group was not age
related. Appropriate patient selection and operator’s expe-
rience are important factors for successful device closure.
In conclusion, despite the limitations of this study, our
results demonstrate that the early successful closure rate and
primary and secondary efficacy success rates were not statis-
tically different in patients with ASD who underwent
transcatheter device closure using the ASO and those
patients who underwent surgical repair. However, the com-
plication rate was lower and the length of hospital stay was
shorter for device closure compared with surgical closure.
Therefore, transcatheter device closure using an ASO seems
to be a safe and effective alternative treatment for secundum
ASD.
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APPENDIX I
Device Group Investigators (listed by the order of numbers of
patients enrolled): Ziyad M. Hijazi, MD, MPH, University
of Chicago Children’s Hospital and New England Medical
Center; Wolfgang Radtke, MD, Medical University of
South Carolina; Donald J. Hagler, MD, Mayo Clinic;
Albert Rocchini, MD, University of Michigan; David
Balzer, MD, Washington University at St. Louis; David
Wax, MD, Children’s Memorial Medical Center; Robert
H. Beekman III, MD, University of Cincinnati Medical
Center; Makram R. Ebeid, MD, University of Mississippi
Medical Center; John Moore, MD, John Murphy, MD, du
Pont Hospital for Children; Jose Ettedgui, MD, Children’s
Hospital of Pittsburgh; John Cheatham, MD, Zahid Amin,
MD, University of Nebraska and Creighton University;
Frank F. Ing, MD, Children’s Hospital–San Diego; Mi-
chael Slack, MD, Joel Lutterman, MD, Arizona Pediatric
Cardiology; Thomas K. Jones, MD, Children’s Hospital
and Medical Center–Seattle; Thomas Doyle, MD, Vander-
bilt Children’s Hospital; John Bass, MD, Fairview Univer-
sity Medical Center; Michael Slack, MD, Children’s Na-
tional Medical Center Washington DC; Daphne Hsu, MD,
Columbia–Presbyterian Medical Center; Ranae Larson,
MD, Loma Linda University Medical Center; John Moore,
MD, St. Christopher’s Children’s Hospital; Hitendra Patel,
MD, New England Medical Center.
The investigators in the surgical group are listed by the order
of numbers of patients as: Thomas Zellers, MD, University of
Texas, SW Medical School; Andrew N. Pelech, MD,
Children’s Hospital of Wisconsin; Albert Rocchini, MD,
University of Michigan; Donald Hagler, MD, Mayo Clinic;
William S. McMahon, MD, The University of Alabama at
Birmingham; Daniel E. Miga, MD, Cook Children’s Heart
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Center; Harm Velvis, MD, Albany Medical Center Hos-
pital; Mark H. Hoyer, MD, University of Florida College of
Medicine; John Moore, MD, St. Christopher’s Children’s
Hospital; David Balzer, MD, Washington University at St.
Louis; Michael S. Vance, MD, Children’s Hospital of the
Kings Daughter; Elman G. Frantz, MD, University of
North Carolina at Chapel Hill; Wolfgang Radtke, MD,
Medical University of South Carolina; Hitendra Patel, MD,
New England Medical Center; Thomas K. Jones, MD,
Children’s Hospital and Medical Center–Seattle; Jose Et-
tedgui, MD, Children’s Hospital of Pittsburgh; John Mur-
phy, MD, duPont Hospital for Children; Makram R.
Ebeid, MD, University of Mississippi Medical Center, John
Bass, MD, Fairview University; Zahid Amin, MD, Univer-
sity of Nebraska and Creighton University; David Wax,
MD, Children’s Memorial Medical Center.
APPENDIX II
Members of Data Safety Monitoring Board: Jamie Lohr, MD,
University of Minnesota, MN; Peter Hesslein, MD, Uni-
versity of Minnesota, MN; Demetre Nicoloff, MD, Cardiac
Surgical Association, Minneapolis, MN; Dorothree Aeppli,
Statistician, St. Paul, MN.
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